Haleon PLC（HLN）股票分析HLNHaleon PLC

Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and others. The Company's segments include North America, Europe, Asia Pacific, and International. Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban. It operates in the Healthcare sector (PERFUMES, COSMETICS, AND OTHER TOILET PREPARATIONS industry).

Haleon PLC (HLN) is a good buy right now due to its strong financial metrics and positive market sentiment. The current price is $10.27, with a forward P/E ratio of 15.70, indicating reasonable valuation. The gross margin has improved to 64.51% in Q2 2025, showing strong profitability. Additionally, hedge funds have increased their buying activity by 142.48% over the last quarter, reflecting confidence in the stock. The main risk is the RSI at 72.32, indicating it may be overbought in the short term, which could lead to price corrections.